Working with complement without being defeated by it: why a complement c3 antibody has to be chosen against the fragment you actually want to detect rather than against the parent protein, how complement technology divides between activation assays, functional assays and detection reagents, what serum handling does to every complement measurement before an assay begins, and which controls make a complement result interpretable rather than merely reproducible

Designing complement work

1. Name the fragment, not the protein. Detecting the intact component, a cleavage product or the neoepitope exposed by activation are three different measurements. Suppliers list them under the same protein name, so read the immunogen and the stated specificity rather than the product title.
2. Fix sample collection before anything else. Complement activates ex vivo. The anticoagulant, the time to processing and the temperature all change the result, and a sample handled casually reports activation that happened in the tube. Standardise collection, process quickly, and aliquot to avoid freeze thaw.
3. Separate functional from quantitative questions. A functional assay asks whether the pathway can proceed to completion; an immunoassay asks how much of a component is present. A deficiency shows in the first and may be invisible in the second, and the two are routinely confused when a result is interpreted.
4. Choose the pathway you are interrogating. The classical, lectin and alternative routes converge but are initiated differently, and an assay that isolates one requires conditions that suppress the others. Using a general activation readout and inferring the pathway is a common error.
5. Include activation and inhibition controls. A positive control that activates the cascade and a sample held under conditions that prevent activation bracket every run. Without them, a low result cannot be distinguished from a failed assay and a high one from a handling artefact.

The sample is the assay

No reagent choice compensates for a sample that activated before it reached the freezer. Because activation is fast and irreversible, the collection protocol is effectively part of the method, and it should be written, followed and recorded with the same care as the assay itself.

Where samples come from elsewhere, agree the handling in advance and ask for the timings. A sample of unknown provenance can be measured precisely and still mean nothing.

Reading a datasheet properly

For complement reagents the useful fields are the immunogen, the stated reactivity against parent and fragments, the applications validated, and whether the clone has been shown not to cross react with the neighbouring components of the cascade.

Where the datasheet is vague, ask the supplier directly and keep the answer with the reagent record. A clone whose specificity nobody can state is a clone whose results nobody can defend.

complement c3 elisa, and what the format changes

A complement C3 ELISA answers a different question from the blot or the stain the same antibodies serve. It reports concentration against a calibrator, which means the pair has to be matched for capture and detection, the standard has to be a defined C3 preparation, and the sample has to be diluted into the working range, which for serum is usually steep. Activation is the trap: C3 fragments are generated in a badly handled sample, so a kit that recognises C3 and its cleavage products reports a total that a kit specific to intact C3 will not.

A c4d antibody and a fragment that stays where it was made

C4d is the covalently bound remnant of activation, which is why it is the reagent for showing complement was active in a tissue rather than measuring what is circulating. A c4d antibody therefore needs a neoepitope clone specific to the bound fragment, and capillary staining is the expected pattern. Frozen and fixed sections behave differently here, so the validated format matters.

A c3d antibody beside the parent protein

C3d is the final bound fragment of the page's own antigen, so an antibody against the whole protein and a c3d antibody answer different questions: one reports the pool, the other reports that the cascade ran and left a mark. Which of the two a figure means has to be stated, because the same tissue can be positive for one and negative for the other.

A von willebrand factor antibody and a multimer, not a protein

This factor circulates as multimers whose size distribution is the clinically relevant property, so a von willebrand factor antibody on a reducing gel destroys the very thing being measured and multimer analysis is run on an agarose gel instead. As a marker, it is the standard endothelial stain in tissue, where a vessel lining is the pattern that says it worked.

A factor ix antibody and a factor viii antibody in the same lane

Both are coagulation factors measured as antigen and as activity, and the two figures diverge whenever a dysfunctional protein is present, so a factor ix antibody and a factor viii antibody report antigen only. Both are cleaved on activation, which means the expected masses depend on whether the sample is plasma, a concentrate or a cell lysate, and that belongs in the method.

A prothrombin antibody and the activation it hides

Prothrombin is converted to thrombin by cleavage, so a prothrombin antibody may see the precursor, the products, or both depending on its epitope, and a figure showing one band on a sample that clotted is reading an incomplete story. Citrated plasma collected properly is the usual sample, and a clotting assay is the activity measurement the antibody cannot replace.

A tpa antibody and the inhibitor bound complex

Tissue plasminogen activator circulates largely bound to its inhibitor, so a tpa antibody may report free enzyme, complexed enzyme or the sum, and the number changes meaning between those. The datasheet has to say which. Activity is measured with a chromogenic substrate, and the two readings disagree exactly where the biology is interesting, which is why both are reported together.

Common questions

Why do complement results vary so much between laboratories?

Sample handling, overwhelmingly. Time to processing, temperature and freeze thaw cycles change activation markers substantially, and these differences are rarely reported in enough detail to be reconciled.

Does an antibody against a component detect its fragments?

It depends entirely on the immunogen and the epitope. Some recognise the parent and every fragment containing that region; others are specific to a neoepitope that exists only after cleavage. The datasheet has to be read, not the product name.

When is a functional assay necessary?

Whenever the question is whether the pathway works, for example in suspected deficiency or when assessing an inhibitor. Component concentrations can look normal while function is absent, and only a functional readout distinguishes the two.

How should serum samples be stored?

Processed quickly, aliquoted in small volumes and held at low temperature, with the number of freeze thaw cycles recorded. Repeated thawing is the most common preventable cause of an uninterpretable complement result.

Browse by service class

• Compare Gene synthesis on advertised prices